Evidence map›Paper›PMID 42809039›Full record

ArticleCurrent microbiology2026

Regulation of Ansamitocin P-3 Biosynthesis by the Response Regulator CrsB in Actinosynnema pretiosum.

Tengfei Wang, Lingjia Zhu, Ruoyi Sun, Shuangying Zhao, Siyu Wang, Ruixin Huang, Meng Liu, Guangxiang Cao, Peipei Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tengfei WangBiomedical Sciences College and Shandong Medicinal Biotechnology Centre, Key Lab for Genetic Engineering and Synthetic Biology of Shandong Province, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China.
Lingjia ZhuSchool of Public Health, Yale University, New Haven, CT, USA.
Ruoyi SunBiomedical Sciences College and Shandong Medicinal Biotechnology Centre, Key Lab for Genetic Engineering and Synthetic Biology of Shandong Province, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China.
Shuangying ZhaoBiomedical Sciences College and Shandong Medicinal Biotechnology Centre, Key Lab for Genetic Engineering and Synthetic Biology of Shandong Province, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China.
Siyu WangBiomedical Sciences College and Shandong Medicinal Biotechnology Centre, Key Lab for Genetic Engineering and Synthetic Biology of Shandong Province, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China.
Ruixin HuangBiomedical Sciences College and Shandong Medicinal Biotechnology Centre, Key Lab for Genetic Engineering and Synthetic Biology of Shandong Province, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China.
Meng LiuSchool of Municipal and Environmental Engineering, Shandong Jianzhu University, Jinan, China.
Guangxiang CaoBiomedical Sciences College and Shandong Medicinal Biotechnology Centre, Key Lab for Genetic Engineering and Synthetic Biology of Shandong Province, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China.
Peipei ZhangBiomedical Sciences College and Shandong Medicinal Biotechnology Centre, Key Lab for Genetic Engineering and Synthetic Biology of Shandong Province, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China. peipeizhang@sdfmu.edu.cn.

Funding

National Natural Science Foundation of China 82204255
6 · The paper itself

Abstract

Ansamitocin P-3 (AP-3) is an ansamycin antibiotic produced by Actinosynnema pretiosum with high clinical and commercial value. Its biosynthesis is tightly controlled, yet the underlying transcriptional network is not fully understood. Here, we identified the two-component system CrsAB and characterized the response regulator CrsB. Deletion of crsB resulted in a 57% reduction in AP-3 yield without impairing morphological development or biomass accumulation. RNA‑Seq showed that CrsB acts as a global regulator, influencing energy metabolism, cell integrity, and biosynthetic capacity. At the fermention at 48 h, genes asm23 and asm43-47 within the biosynthetic gene cluster, which are primarily responsible for the synthesis of AHBH from UDP-glucose, were significantly downregulated upon crsB deletion. Conversely, genes of the pentose phosphate pathway, zwf, opcA and pgl, were markedly upregulated, whereas their expression levels showed no significant differences between the two strains at 72 h. These temporal transcriptional changes were confirmed by qRT‑PCR. Collectively, our data suggest that CrsB positively coordinates primary and secondary metabolism primarily during the early stage to promote AP-3 production, offering new targets for metabolic engineering.

Indexed as

ActinobacteriaAnti-Bacterial AgentsBacterial ProteinsGene Expression Regulation, BacterialMaytansineGene DeletionMultigene FamilyansamitocinsAnti-Bacterial AgentsBacterial ProteinsMaytansine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.